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METHYLPHENIDATE AND SLEEP IN ADHD
INTRODUCTION
ACTIGRAPHS ARE SMALL DEVICES, USUALLY WORN 
AROUND THE WRIST, THAT DETECT AND STORE MOVE-
MENT FOR LATER ANALYSIS OF LEVELS OF ACTIVITY, 
sleep and wake parameters, and circadian rhythm parameters.1 
These measurement goals make actigraphy a useful tool for objec-
tively studying attention deﬁcit hyperactivity disorder (ADHD), 
since this disorder is by deﬁnition associated with hyperactivity 
and with sleep problems.2 Actigraphy has indeed been utilized in 
studying children with ADHD, but it has rarely been employed 
in adults with the disorder. We therefore conducted an extensive 
actigraphy study of daytime and nighttime activity, sleep/wake 
parameters, and circadian rhythms in adults carefully diagnosed 
with ADHD; we also collected data to measure the effects of 
stimulant medication. We gathered these data to provide tentative 
answers to the 4 research questions described below.
1) Are adults with ADHD more active (as measured by acti-
graphs) during the day and/or during the night than normal con-
trols? Children with ADHD show higher levels of daytime activ-
ity than normal controls.3 We know of only one study that used 
daytime actigraphy in an adult population suspected of childhood 
ADHD. The patient group in this study could be distinguished 
from normal controls by higher activity counts from the acti-
graphs.4 However, the patient group in this study was primarily 
classiﬁed as “Antisocial Violent Offenders,” thus our study is the 
ﬁrst to explore daytime activity in adult participants with a pri-
mary diagnosis of ADHD.
With respect to nighttime activity, Cohen-Zion and Ancoli-Is-
rael discussed 4 studies that utilized actigraphs in a child ADHD 
sample and they reported that the evidence was inconclusive, 
although most studies reported more nighttime activity and in-
creased nighttime variability in activity levels.5 Two studies have 
used actigraphy to evaluate nocturnal activity in an adult ADHD 
population; in one study the ADHD group showed higher mean 
activity levels than normal controls,6 whereas the other study re-
ported no difference.7 Both studies reported a higher movement 
index (percentage of epochs with an activity count > 0) during 
the night.
2) Are there differences in actigraphic sleep parameters be-
tween adults with and without ADHD? Problems with sleep are 
frequently reported in children with ADHD.2 In particular, pa-
rental reports of sleep problems in children with the disorder are 
highly prevalent, although results of more objective measure-
ments of sleep (e.g., polysomnography) are equivocal; there does 
not seem to be one speciﬁc disturbance of sleep architecture relat-
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ed to the disorder. ADHD has also been associated with a higher 
prevalence of sleep disorders like periodic limb movement8 and 
sleep disordered breathing.9 It has even been suggested that sleep 
problems in children with ADHD may be the primary condition 
that results in secondary symptoms of hyperactivity and inatten-
tion, rather than ADHD being the primary condition associated 
with speciﬁc sleep problems.5 
Several studies have indicated that sleep disorders in adults 
may also be misdiagnosed as ADHD.10 In adult men with antiso-
cial personality disorders, Lindberg et al. found a strong positive 
correlation between childhood ADHD scores and abnormal sleep 
architecture (increased percentage of stage 4 sleep) as measured 
by polysomography.11 Kass et al. also established a relation be-
tween scores on an adult ADHD questionnaire and scores on sev-
eral sleep problem questionnaires (speciﬁc sleep problems were 
not mentioned in this study).12 We know of no direct studies of 
sleep characteristics of adults carefully diagnosed with ADHD. 
3) Are there differences in circadian rhythm parameters between 
adults with ADHD and normal controls? Actigraphy also yields 
information on the amplitude, phase, and stability of the circadian 
(24-hour) pattern of activity, which may reﬂect functionality of 
the hypothalamic suprachiasmatic nucleus, the biological clock of 
the brain. There is little research into circadian rhythms in ADHD. 
Van der Heijden et al. established that the nocturnal onset of mela-
tonin secretion was delayed in children with ADHD.2 The authors 
suggested that the chronic sleep onset insomnia often encountered 
in children with ADHD may be a delayed sleep phase circadian 
rhythm disorder. 
4) What are the effects of treatment with methylphenidate on 
the above-mentioned activity, sleep, and circadian rhythm param-
eters in adults with ADHD? Methylphenidate (Mph) has been the 
preferential treatment for ADHD for decades, both for children 
and adults.13,14 Very few studies have investigated the effects of 
this stimulant on hyperactivity by means of actigraphy, but the 
few available outcomes indicated a decrease in activity during the 
day with treatment in children with ADHD.15 We know of no day-
time medication effect studies in the adult ADHD population, but 
the one available actigraphy treatment study reporting effects of 
stimulants during the day (last dose at 16:00) showed a decrease 
of nighttime activity level with medication in comparison to pla-
cebo.6 Daytime activity data were not reported.
Insomnia is a frequent side effect of stimulant medication.16 
Other sleep disturbances, like tossing or moving and shorter sleep 
time, have also been indicated as side effects of stimulant treat-
ment.17 Some researchers have suggested that sleep problems may 
represent features of the behavioral phenotype of ADHD rather 
than adverse side effects of medication.18 Actigraphy studies on 
the effects of stimulants on sleep in children with ADHD have 
noted differences in total sleep time, which decreased with medi-
cation.19 Actigraphic studies of medication in adults are not avail-
able.
METHODS 
Participants
ADHD participants
We included data of 33 adults with ADHD, 16 men and 17 
women (we strove for inclusion of equal number of each sex). 
The average age was 37.9 years (SD 10.3), and the average IQ 
was 104.1 (SD 18.5). One of the participants was diagnosed with 
ADHD hyperactive / impulsive subtype, the other 32 were diag-
nosed with ADHD combined subtype. Thirty-one of these par-
ticipants entered the medication trial after a baseline comparison. 
One female participant had to be excluded from the medication 
trial due to use of a weight control supplement that contained 
a stimulating substance (ephedra), and one male participant was 
excluded because of a positive opiate urine screening during the 
ﬁrst week of the trial. 
The average age for the 31 participants of the medication trial 
was 37.8 (SD 10.6), the average IQ was 104.1 (SD 18.2). None 
of the participants had been treated with methylphenidate (Mph) 
prior to this study. The participants were self-referred or referred 
by other clinicians for assessment of ADHD to an outpatient 
clinic in the Netherlands. Details of the diagnostic procedure and 
the instruments used have been provided elsewhere.14,20 In brief, 
participants underwent a standardized clinical assessment by a 
psychiatrist. In addition to a semi-structured clinical diagnostic 
interview for ADHD and comorbid disorders, including sleep 
complaints, several structured interviews and questionnaires 
were used to assess ADHD and comorbid psychiatric disorders. 
To be given a diagnosis of adult ADHD, subjects had to (1) cur-
rently meet at least 5 of 9 DSM-4 criteria of inattention and / or 
at least 5 of 9 DSM-4 criteria of hyperactivity / impulsivity (this 
cutoff point is in line with previous research21); (2) meet at least 6 
of 9 DSM-4 criteria of inattention and / or at least 6 of 9 DSM-4 
criteria of hyperactivity / impulsivity in childhood; (3) describe a 
persistent course of ADHD symptoms from childhood to adult-
hood; and (4) endorse a moderate to severe level of impairment 
attributed to ADHD symptoms.
Normal Control Participants
Thirty-nine normal control (NC) participants, 18 men and 21 
women, participated in the baseline comparison study. The aver-
age age was 37.8 years (SD 9.5), and the average IQ was 109.3 
(SD 15.4). Controls were matched to ADHD participants by age 
and sex on group level. We only included NCs that did not a) show 
any evidence of ADHD or other psychiatric diagnoses, b) use any 
drugs or psychotropic medications, c) consume more alcohol than 
considered safe by ofﬁcial Dutch guidelines, d) ever receive a 
psychiatric diagnosis (including substance abuse), or e) seek help 
for mental health problems (including burnout) during the last 3 
years. IQ as estimated with a short version of the Wechsler Adult 
Intelligence Scale-3 had to be above 75.
The local Medical Ethical Committee approved the study, and 
all subjects completed a written informed consent form before 
inclusion in the study.
Procedure
All participants wore the actigraph for 7 consecutive nights 
and days to obtain baseline values. The ADHD participants then 
entered a double-blind, placebo-controlled, cross-over trial of 
Mph. The design of this trial and clinical outcomes are described 
in detail elsewhere.14,20 In brief, there were two 3-week treatment 
periods for each participant, one period of 3 weeks for Mph and 
one period of 3 weeks for placebo, with 1 week of washout in 
between. The order of treatment (Mph-placebo or placebo-Mph) 
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was randomized. Study medication was titrated from low to high 
doses to avoid exposure to high initial doses of active medication 
and to minimize side effects. Participants started with 0.5 mg/kg/d 
in week 1, followed by 0.75 mg/kg/d in week 2, and up to 1.0 
mg/kg/d in week 3, unless adverse effects emerged. Medication 
was dosed 4 or 5 times daily (depending on rebound effects). The 
last dose was always prescribed at 20:00. Subjects used a device 
(Memos) containing compartments for tablets and a timer in order 
to take the medication on time. Compliance was monitored by 
electronic registration of the opening of the device at each visit 
to the pharmacy. Compliance was deﬁned as opening the device 
within 15 min of the timer’s signal > 80% of the time. Repeat-
ed measurements with the actigraphs took place during week 3 
(highest dose of Mph, or placebo) and during week 7 (highest 
dose of Mph, or placebo). All recordings were obtained between 
July 2000 and February 2003.
Materials 
Actigraphy
We used the Actiwatch Activity Monitoring System, devel-
oped by Cambridge Neurotechnology. We set our epoch length 
to 1 min, in accordance with the 2002 Practice Parameters for the 
use of actigraphy.22 Epoch length refers to the period of time the 
Actiwatch accumulates activity data before saving the sampling 
and resetting the counter to zero. We instructed participants to 
wear the Actiwatch on the non-dominant wrist, as recommended 
by Littner et al.22 
Calculation of Actigraphic Sleep Variables
Objective estimates of sleep were calculated from the actigra-
phy recordings using the Actiwatch Sleep Analysis software (ver-
sion 1.19, 2001, Cambridge Neurotechnology, Cambridge, UK). 
The Actiwatch and accompanying software compare favorably to 
other such packages in reliably recording activity23 and estimating 
sleep.24 The patterning of periods of rest and activity during the 
night is correlated — but not identical — to periods of sleep and 
wakefulness: estimates are useful though,25 and will be referred to 
as “sleep” and “wakefulness” throughout this paper. We obtained 
the objective sleep variables described in Table 1 for each subject 
at each condition by averaging over the recorded nights.
Since sleep is not a continuous process, the actual sleep time 
is usually lower than the time spent in bed. The mean sleep and 
wake bout duration give an impression of the structure of sleep. 
The sleep bout duration measures the average length of uninter-
rupted sleep between 2 consecutive awakenings. Sleep bouts of 
long duration are related to high sleep efﬁciency, the occurrence 
of “deep,” i.e., slow wave sleep, and are negatively related to noc-
turnal awakenings.26 The wake bout duration provides another in-
dication of sleep depth and continuity; long arousals are more 
disruptive to sleep than very brief ones.
Calculation of Actigraphic Circadian Sleep-Wake Rhythm Variables
Activity during the major sleep period and the patterning of 
rest and activity over days and nights may provide useful informa-
tion. We calculated a number of nonparametric circadian rhythm 
variables, which compare favorably to other methods for rhythm 
quantiﬁcation, including cosine ﬁtting, complex demodulation, the 
Lomb-Scargle periodogram and autoregression.27 The interdaily 
stability (IS) quantiﬁes the strength of coupling of the sleep-wake 
rhythm to the 24-hour regularity in the environment. A low IS is 
indicative of a weak circadian rhythm. The intradaily variability 
(IV) quantiﬁes the fragmentation of periods of rest and activity. A 
high IV is indicative of many transitions between periods of rest 
and activity. For details on calculation of these variables, the reader 
is referred to our previous work.23,27-29 A measure indicating the ac-
tivity level during the major sleep period is L5, deﬁned as the mean 
activity level during the sequence of the 5 least active hours in the 
24-hour average activity proﬁle. L5 provides an indication of rest-
fulness and regularity of sleep periods with lower values indicating 
a more regular “core” sleep period. L5-Onset indicates the clock 
hour at which this major restful phase commences. A measure in-
dicating the activity level during the major wake period is M10, 
deﬁned as the sequence of the 10 most active hours in the 24-hour 
average activity proﬁle. M10 provides an indication of how active 
and regular the major wakefulness periods are. M10-Onset indi-
cates the clock hour at which this major active phase commences. 
Finally, the relative amplitude (RA) quantiﬁes the difference be-
tween daytime (M10) and nighttime (L5) activity levels. A low RA 
indicates little difference between activity levels during the major 
rest and activity phases and/or extreme irregularity; both of these 
are indicative of a weak circadian rhythm. 
Sleep and Activity Log
In accordance with the 2002 Practice Parameters for the use 
of actigraphy,22 we asked participants to complete a sleep and ac-
Table 1—Description of objective actigraphy and associated subjec-
tive sleep parameters (ﬁrst 3 parameters).
Parameter Description
Bedtime (hr) as noted by participant in log
Get up time (hr) as noted by participant in log
Time in bed (hrs) difference between get up time and bed-
time
Sleep start (hr) as estimated from actigraph data
Sleep end (hr) as estimated from actigraph data
Assumed sleep time (hrs) difference between sleep end and sleep 
start
Actual sleep time (hrs) assumed sleep time minus periods of 
wakefulness during the night
Actual sleep %  percentage of sleep between sleep start 
and sleep end
Wake bouts (number of) number of times participant wakes up 
during sleep
Actual wake time (hrs) hours of wakefulness during assumed 
sleep time
Actual wake % percentage of wakefulness during as-
sumed sleep time
Sleep efﬁciency percentage of sleep between bedtime 
and sleep end
Sleep onset latency (hrs) the time it takes from bedtime to sleep 
start
Sleep bout duration (hrs) average length of uninterrupted sleep 
between two consecutive awakenings
Wake bout duration (hrs) mean duration of periods of wakeful-
ness
Adult ADHD and Actigraphy—Boonstra et al
SLEEP, Vol. 30, No. 4, 2007 436
tivity log twice a day (morning and evening) for each day they 
wore the actigraph. The log contained questions about subjective 
experience of different aspects of sleep, rated on a 5-point Likert 
scale (e.g., “How well rested did you feel today?”, “How well did 
you sleep?”). High scores indicated poor subjective experience. 
The log also contained questions about activities during the day, 
use of medication, alcohol, caffeinated beverages, cigarettes, and 
bed- and wake times. In the log, participants noted periods they 
did not wear the actigraph, due to showering and other water-re-
lated activities. These periods of time were manually discarded 
from the data before analysis.
Statistical Approach
Since it has been noted previously that sleep-wake rhythms 
may differ with age, sex, and season,30 and since we obtained data 
throughout the year, it was desirable to include these factors as co-
variates. Season is a circular variable, which has previously suc-
cessfully been linearized into 2 variables: day length and rate of 
change in day length.23,28 In a repeated measures design, however, 
these season variables are time-varying covariates. A solution was 
found in the application of hierarchical regression analysis (i.e., 
random coefﬁcient analysis) to account for the interdependency of 
the data points inherent to the hierarchical structure of the design, 
i.e. sequential observations within subjects (MLwiN software, 
Centre for Multilevel Modelling, Institute of Education, London, 
UK).31 Although not strictly necessary, we consistently applied 
this method to ﬁrst investigate differences between baseline as-
sessments of ADHD participants and control subjects.
For all variables mentioned above we obtained effect estimates 
from the following regression equation:
Outcome_Variable
j
 = ß
0j
 + ß
1j
*ADHD + ß
2j
*Male + ß
3j
*Age + 
ß
4j
*Daylength + ß
5j
*DaylengthChange (1)
where ß
0j 
– ß
5j
 are the effect estimates for the intercept, the ef-
fect of ADHD, sex, age and season, optimized to ﬁt the observa-
tions of all j subjects. 
We subsequently investigated the effect of Mph in the ADHD 
participants on the same variables. For all variables we obtained 
effect estimates from the following regression equation:
Outcome_Variable
ij
 = ß
0j
 + ß
1ij
*Mph + ß
2ij
*Male + ß
3ij
*Age + 
ß
4ij
*Daylength + ß
5ij
*DaylengthChange + ß
6ij
*Placebo + 
ß
7ij
*Time (2)
where ß
0 
– ß
7
 are the effect estimates for the intercept, the ef-
fect of Mph, sex, age, season, placebo, and time in study (whether 
methylphenidate was taken during the ﬁrst or second period of 
the trial), as optimized to ﬁt all i observations of all j subjects. 
Effect estimates with two-tailed Wald–statistic P-values < 0.05 
were regarded as signiﬁcant; non-signiﬁcant terms were excluded 
from the regression equation and a next iteration of ﬁtting the 
resulting sparser equation commenced.
RESULTS
Baseline comparisons
Independent-samples t-tests demonstrated that there were no 
differences between the 2 groups in age (t
1,70
 = 0.04, P = 0.97) or 
IQ (t
1,70
 = -1.31, P = 0.19).
Since daily activities inﬂuence actigraphy parameters, we 
compared the ADHD and NC groups with respect to occupation. 
Table 2 presents the occupation of participants, coded according 
to the Standard Occupational System (U.S. Department of Labor, 
Bureau of Labor Statistics). We also coded occupation according 
to physical load of the activities (e.g., none, light, medium, heavy, 
and unknown). A 2 (ADHD versus NC) by 5 (physical load code) 
contingency tables analysis indicated no differences in distribu-
tion of physical load between the two groups [Pearson’s χ2 (4, N = 
72) = 4.67, P = 0.32, Cramer’s V = 0.26]. None of the participants 
worked nightshifts.
Table 3 presents the grand means and standard errors for all 
variables at baseline and after treatment with Mph (the numbers 
provided are raw data). The effect estimates of the variables ﬁ-
nally included in the regression analysis for the baseline group 
comparisons are shown in Table 4, providing information on 
which factors inﬂuenced the ﬁnal outcomes. An example of how 
to interpret Table 4 and Table 5 is provided in a note following 
Table 4.
As can be expected for ADHD, the daytime activity level M10 
was 52 counts (17%) higher in the ADHD group than in control 
subjects. No differences were found in nighttime activity levels.
After having accounted for the variance due to age, sex, and 
season, the actigraphic sleep variables indicated less sound sleep 
in the ADHD group. Compared to NCs, ADHD participants 
showed a 3.5% lower sleep efﬁciency, a 6-min (67%) longer sleep 
onset latency, and a 6-min (34%) shorter average sleep bout dura-
tion uninterrupted by wakefulness.
The circadian variables, on the other hand, did not indicate dis-
turbances of circadian organization of the sleep-wake cycle. On 
the contrary, compared to NCs, participants with ADHD showed 
0.07 points (13%) increase in IS and 0.13 points (16%) decrease 
in IV, respectively, indicative of a more repeatable daily schedule 
of activities and more consolidated periods of rest and activity. 
The subjective variables indicated that ADHD participants felt 
less well-rested in general (0.82 or 36%) as well as directly after 
waking up (0.72 or 30%), and that they rated their sleep qual-
ity lower (0.61 or 31%) than control subjects. This is consistent 
with the objectively lower sleep efﬁciency than normal subjects. 
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Table 2—Occupation of ADHD participants and normal controls.
Occupation Category Percentage of group
 ADHD Controls
unknown occupation 6.1 12.8
management occupation 12.1 15.4
business & ﬁnancial operations occupation 3.0 12.8
computer & mathematical occupation 6.1 0.0
community & social services occupation 3.0 2.6
education, training, & library occupation 12.1 2.6
arts, design, entertainment, sports, 
   & media occupation 6.1 2.6
healthcare practitioners & technical 
   healthcare occupation 18.2 20.5
healthcare support occupation 3.0 0.0
food preparation & serving related occupation 0.0 5.1
protective service occupation 3.0 0.0
personal care & service occupation 3.0 0.0
sales & related occupation 6.1 5.1
ofﬁce & administrative support occupation 12.1 17.9
construction & extraction occupation 6.1 0.0
transportation & material moving occupation 0.0 2.6
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ADHD participants showed an 8-minute (65%) longer subjective 
sleep onset latency and 0.60 points (36%) more difﬁculty fall-
ing asleep. These ﬁndings are consistent with the objectively in-
creased sleep latency of 6 minutes.
Medication Comparisons
The mean weight of the ADHD participants was 77.5 kg (SD 
= 12.8). The mean dose of Mph administered in the 3rd week of 
the medication phase of the trial was 0.94 mg/kg/day (SD = 0.15). 
Twenty of 28 participants (64.5%) were compliant, according to 
the deﬁnition in the Methods section. The other 8 opened their 
Memos device outside the 15-min limit. Compliance data were 
missing for 3 participants. 
The clinical effects of treatment with Mph in this sample have 
been described earlier.14 In brief, the response rate of Mph varied 
between 38% and 51%, and using placebo between 7% and 18%, 
depending on outcome measure used. Side effects were reported 
in 82% of the group with Mph, compared to 69% with placebo. 
Sleeping problems were reported in 33% of the cases with Mph, 
compared to 22% with placebo.
Table 5 shows the effect of Mph and the covariates age, sex, 
and season resulting from the regression analyses. Neither pla-
cebo treatment nor time in study affected any of the variables, and 
therefore, these factors were not included in the table. 
There was no change in activity level during the day (M10) 
with medication. The actigraphic sleep variables indicated that 
Mph is associated with delays in bedtime (19 min), sleep onset la-
tency (5 min or 34%) and sleep start (24 min). Consequently, the 
assumed sleep time was reduced by 25 min (6%) and the actual 
sleep time by 20 min (5%). However, during this shorter sleep 
period, sleep appeared to be more consolidated as indicated by a 
decrease in the number of nocturnal awakenings (-3.8 or 14%), a 
lower percentage of wakefulness (-0.9 or 8%), and a 3-min (21%) 
increased average duration of uninterrupted sleep bouts. 
The circadian variables showed that treatment delayed the on-
set of the 5 least active hours (L5) by 18 min, in accordance with 
the delayed bedtime and sleep start reported above. Treatment in-
creased the fragmentation of periods of rest and activity (IV) by 
0.07, or 9%. 
Table 3—Means and standard errors of the subjective and objective variables in control subjects and ADHD subjects (ﬁrst 2 columns of data). The 
rightmost 2 columns of data give means and standard errors of the variables after placebo versus Mph treatment.
 Group/Assessment
 Baseline ADHD Treatment
 Controls ADHD Placebo Methylphenidate
Variable (unit of measurement)
Subjective variables
Well-rested (a.u.) 2.26±0.08 3.07±0.13c 2.84±0.15  3.03±0.14
Sleep onset latency (hrs) 0:12±0:01 0:20±0:04a 0:17±0:03 0:24±0:04
Difﬁculty initiating sleep (a.u.) 1.66±0.10 2.29±0.19b 2.15±0.19 2.33±0.19
Nocturnal awakenings (a.u.) 1.02±0.12 1.34±0.17 0.99±0.16 0.82±0.14b
Sleep quality (a.u.) 1.97±0.06 2.56±0.13c 2.47±0.14 2.67±0.13
Rested at wake up (a.u.) 2.41±0.08 3.12±0.12c 3.01±0.14 3.12±0.13
Sleep variables
Bedtime (hr) 00:23±00:07 00:16±00:08 00:14±00:59 00:34±01:03b
Get up time (hr) 08:24±00:09 08:18±00:10 08:15±00:55 08:12±01:02
Time in bed (hrs) 8:01±0:07 8:01±0:09 8:00±0:53 7:38±1:03b
Sleep start (hr) 00:33±00:07 00:30±00:08 00:30±00:59 00:55±01:01c
Sleep end (hr) 08:20±00:09 8:11±00:09 8:08±00:55 08:06±01:01
Assumed sleep time (hr) 7:47±0:07 7:40±0:08 7:37±0:50 7:11±0:56c
Actual sleep time (hrs) 6:53±0:06 6:45±0:07 6:44±0:44 6:23±0:42c
Actual sleep % (%) 89±1 88±1 88±4 89±4a
Actual wake time (hrs) 0:53±0:03 0:55±0:03 0:53±0:21 0:47±0:25a
Actual wake % (%) 11±1 12±1 12±4 11±4a
Sleep efﬁciency (%) 86±1 84±1b 84±5 86±6
Sleep onset latency (hrs) 0:10±0:01 0:14±0:01c 0:15±0:11 0:20±0:16a
Wake bouts (#) 28±1 27±1 27±8 23±9c
Sleep bout duration (hrs) 0:19±0:02 0:16±0:00a 0:16±0:04 0:20±0:07c
Wake bout duration (hrs) 0:01±0:00 0:02±0:00 0:02±0:00 0:02±0:00
Circadian variables
IS 0.51±0.02 0.57±0.02b 0.56±0.02 0.55±0.02
IV 0.81±0.03 0.69±0.03b 0.72±0.03 0.77±0.03a
L5 16±2 16±1 15±2 13±1
M10 303±17 353±17a 341±15 325±19
RA 0.90±0.01 0.91±0.01 0.91±0.01 0.01±0.01
L5 Onset 01:46±00:09 01:33±00:09 01:34±00:12 01:51±00:10a
M10 Onset 09:49±00:14 09:58±00:17 09:58±00:18 10:03±00:19
a = p<0.05, b = p<0.01, c = p<0.001
 A.u. = arbitrary units; hr = clock time; hrs = hours (duration); IS = interdaily stability; IV = intradaily variability; L5 = the least active 5-hour period 
of the average activity proﬁle; M10 = the most active 10-hour period of the average activity proﬁle; RA = relative amplitude
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Subjectively, Mph reduced the nocturnal awakening rating by 
0.36 or 31%, which is in agreement with the objective decrease in 
wake time and percentage. 
As in previous observations, the covariates sex, age, and 
season accounted for a signiﬁcant part of the variance in the 
sleep-wake rhythm. Although a full description of these effects 
is outside the scope of this paper, the most signiﬁcant ﬁndings 
(P<0.001) will brieﬂy be discussed here. With regard to sex dif-
ferences, males went to bed more than a half-hour later than 
females in the overall analysis (including both control subjects 
and the baseline assessments of the ADHD subjects). With re-
gard to age, in the ADHD group, sleep efﬁciency increased by 
0.20% per year of age, the number of awakenings decreased by 
0.4/y, and the duration of uninterrupted sleep bouts increased by 
16 seconds/y of age. With regard to season, in the ADHD group, 
sleep end and get up time were advanced by 8 min for each hour 
increase in day-length, indicating an earlier awakening in the 
summer than the winter. 
To explore the relationship between clinical improvement and 
improvement in sleep parameters with Mph, we calculated corre-
lations between difference scores in several sleep parameters and 
clinical response as measured in Kooij et al.14 Correlations were 
low, and none of them reached signiﬁcance (data available from 
the ﬁrst author).
Explorative Analyses of Comorbidity
To obtain a ﬁrst indication of the inﬂuence of comorbid disor-
ders on actigraphic parameters in the ADHD group, we calculated 
correlations between the actigraph parameters that showed sig-
Table 4—Regression parameter estimates (± standard error) of the subjective and objective variables comparing control subjects and ADHD sub-
jects and effects of sex, age, and season over all subjects in both groups.
Regression Model
 Intercept ADHD Male Age Daylength Daylength Change
Variable (unit of measurement)
Subjective variables
Well-rested (a.u.) 2.43±0.12 0.82±0.14c -0.37±0.14b
Sleep onset latency (hrs) 0:12±0:02 0:08±0:04a
Difﬁculty initiating sleep (a.u.) 1.67±0.13 0.60±0.19b    0.52±0.26a
Nocturnal awakenings (a.u.) 1.17±0.10
Sleep quality (a.u.) 2.10±0.10 0.61±0.13c -0.29±0.13a
Rested at wake up (a.u.) 2.58±0.11 0.72±0.13c -0.37±0.13
Sleep variables
Bedtime (hr) 0:05±0:06  0:33±0:09c   0:34±0:13b
Get up time (hr) 9:16±0:24   -0:01:25±0:00:37a
Time in bed (hrs) 8:59±0:20   -0:01:30±0:00:31b
Sleep start (hr) 0:16±0:06  0:34±0:09c   0:30±0:13a
Sleep end (hr) 9:11±0:23   -0:01:24±0:00:36a
Assumed sleep time (hr) 8:36±0:18  -0:21±0:10a -0:01:06±0:00:29a
Actual sleep time (hrs)
7:04±0:06  -0:29±0:09b
Actual sleep % (%) 85±2    0.4±0.2a
Actual wake time (hrs) 1:15±0:10    -0:01±0:00a
Actual wake % (%) 16±2    -0.4±0.2a
Sleep efﬁciency (%) 80±2 -3.5±1.1b   0.6±0.2b
Sleep onset latency (hrs) 0:23±0:04 0:06±0:02c  -0:00:11±0:00:05a -0:00:45±0:00:21a -0:05±0:02a
Wake bouts (#) 46±5   -0.3±0.1b -0.7±0.3a 
Sleep bout duration (hrs) 0:06±0:04 -0:06±0:02a   0:01±0:00b
Wake bout duration (hrs) 0:01±0:00
Circadian variables
IS 0.51±0.02 0.07±0.02b
IV 0.81±0.03 -0.13±0.04b
L5 23±5  5±2a -0.2±0.1a
M10 301±17 52±24a
RA 0.96±0.03  -0.05±0.01b 0.002±0.001a
L5 Onset 1:41±0:06
M10 Onset 9:56±0:10
a = P<0.05, b = P<0.01, c = P<0.001
A.u. = arbitrary units; hr = clock time; hrs = hours (duration); IS = interdaily stability; IV = intradaily variability; L5 = the least active 5-hour period 
of the average activity proﬁle; M10 = the most active 10-hour period of the average activity proﬁle; RA = relative amplitude. As an example of 
the interpretation of the regressions, consider the model estimate of sleep bout duration in an ADHD subject aged 30, as measured on August 13, 
when Daylength is 14.85 hours and DaylengthChange is -0.42 hrs/week. Filling out the intercept, variables and parameter estimates in the regres-
sion formula (Outcome_Variable
j
 = ß
0j
 + ß
1j
*ADHD + ß
2j
*Male + ß
3j
*Age + ß
4j
*Daylength + ß
5j
*DaylengthChange) yields the following outcome:  
Sleep bout duration (hrs) = 0:06 + (-0:06*1) + (0*1) + (0*30) + (00:01*14.85) + (0*-0.42) = 00:06 - 00:06 + 00:01 * 14.85) = 00:15 (rounded to 
ﬁfteen minutes).
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niﬁcant differences in the baseline analyses and the participants’ 
scores on the Hamilton Depression Scale and the Hamilton Anxi-
ety Scale. These rating scales were part of the diagnostic proce-
dure for ADHD and comorbidity. Depression and anxiety were 
selected because these disorders are known for their impact on 
sleep.32,33 The correlations between the scales and the actigraphy 
parameters ranged between |.02| and |.27|. None of the correla-
tions reached signiﬁcance (data available form the ﬁrst author).
Subjective Sleep Complaints
Subjective sleep complaints were questioned in the semi-struc-
tured clinical diagnostic interview. The most prominent ﬁndings 
were that two-thirds of the ADHD participants said they have 
always had difﬁculty sleeping (65%), and that trouble going to 
bed on time (87%) and difﬁculty getting out of bed (71%) were 
experienced by the vast majority of the participants, suggesting 
a phase-delayed sleep-wake cycle. Half of the subjects reported 
daytime sleepiness.
DISCUSSION
The present study provides some initial answers to questions 
concerning activity, sleep, and circadian rhythms, as measured 
with actigraphs and subjective reports in an adult ADHD popula-
tion. To our knowledge, this study is the ﬁrst to objectively estab-
lish increased daytime activity in adults with ADHD, which an-
swers our ﬁrst research question. Our results are consistent with 
studies conducted in the child ADHD population.3 We did not ﬁnd 
a difference in nighttime activity L5 between our ADHD partici-
pants and the NCs. This result deviates from what we would expect 
based on the literature on children with the disorder, in which it is 
suggested that one of the more consistent ﬁndings in this popula-
tion is increased nighttime activity.5 Data on adults with ADHD 
are equivocal, with one study6 reporting more nighttime activity 
and the other7 not. However, direct comparison with these stud-
ies is difﬁcult since different dependent variables were reported. 
Moreover, sample size in both studies was small, so our data may 
prove more reliable. A possible explanation for the difference be-
tween children and adults could be found in the fact that adults 
Table 5—Regression parameter estimates (± standard error) of the subjective and objective variables comparing Mph treatment versus baseline 
and placebo in ADHD subjects. Regression models corrected for effects of sex, age, and season.
Regression Model
 Intercept Methylphenidate Male Age Daylength Daylength Change
Variable (unit of measurement)
Subjective variables
Well-rested (a.u.) 3.20±0.14  -0.46±0.20a
Sleep onset latency (hrs) 0:20±0:03
Difﬁculty initiating sleep (a.u.) 2.25±0.15
Nocturnal awakenings (a.u.) 1.14±0.14 -0.36±0.13b
Sleep quality (a.u.) 2.56±0.11
Rested at wake up (a.u.) 3.09±0.11
Sleep variables
Bedtime (hr) 0:14±0:10 0:19±0:06b
Get up time (hr) 9:55±0:28    -0:08±0:02c
Time in bed (hrs) 10:01±0:33 -0:20±0:07b -0:31±0:14a -0:01:22±0:00:39a -0:04±0:02a
Sleep start (hr) 0:30±0:09 0:24±0:07c
Sleep end (hr) 9:44±0:27    -0:07±0:02c
Assumed sleep time (hr) 8:42±0:27 -0:25±0:06c -0:32±0:13a  -0:03±0:02a
Actual sleep time (hrs)
6:44±0:06 -0:20±0:06c
Actual sleep % (%) 83±2 1±0a  0±0a  -2.8±1.2a
Actual wake time (hrs) 1:39±0:13 -0:05±0:02a  -0:00±0:00a -0:01±0:00a 0:15±0:06a
Actual wake % (%) 17±2 -1±0a  0±0a  2.8±1.2a
Sleep efﬁciency (%) 77±2   0.20±0.06c
Sleep onset latency (hrs) 0:33±0:06 0:05±0:02a  -0:00:29±0:00:09b
Wake bouts (#) 42±4 -4±1c  -0.4±0.1c  4.3±2.1a
Sleep bout duration (hrs) 0:06±0:02 0:03±0:00c  0:00±0:00c
Wake bout duration (hrs) 0:02±0:00
Circadian variables
IS 0.60±0.02  -0.07±0.03b
IV 0.71±0.02 0.07±0.03a
L5 15±1
M10 381±13  -96±19c
RA 0.91±0.01
L5 Onset 1:33±0:09 0:18±0:07a
M10 Onset 9:56±0:10
a = P<0.05, b = P<0.01, c = P<0.001
A.u. = arbitrary units; hr = clock time; hrs = hours (duration); IS = interdaily stability; IV = intradaily variability; L5 = the least active 5-hour period 
of the average activity proﬁle; M10 = the most active 10-hour period of the average activity proﬁle; RA = relative amplitude
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choose their own bedtime and daytime activities, which may lead 
to less activity during the night. It may also be that activity in the 
5 least active hours of the average 24-hour rest-activity proﬁle 
provides a view of activity during the core sleep period, but is not 
sensitive enough to quantify whole-night nocturnal activity, as is 
indeed suggested by the ﬁndings discussed below.
With respect to our second research question, our results in-
dicate that there are indeed differences in actigraphic sleep pa-
rameters between adults with and without ADHD. Adults with 
ADHD show lower sleep efﬁciency, longer sleep onset latency, 
and shorter average duration of within-night uninterrupted sleep 
periods. In children with ADHD, actigraphy studies have shown 
mixed results, but longer sleep onset latencies have been reported 
frequently.5 
Our third research question (“Are there differences in circadian 
rhythm between adults with ADHD and normal controls?”) also 
leads to a positive answer, although this answer in part differs 
from what one would intuitively expect in this population. In the 
nonparametric circadian rhythm analyses, we found that partici-
pants with ADHD showed a more repeatable daily schedule of 
activities and more consolidated periods of rest and activity than 
the NCs. In children with ADHD, there have been some sugges-
tions of deviant circadian patterns.2 
The fact that our data do not point towards deviant circadian 
patterning in adults with the disorder may be related to some form 
of compensation of adults with ADHD. They may be trying to 
impose external structure to counterbalance their lack of inter-
nal structure, as has been reported to occur in healthy aging as 
well.34 Alternatively, it may be that there was less difference in 
high and low activity levels in the ADHD group because their 
daytime activity was near maximal most of the time. Indeed, it has 
been previously found in demented elderly that interdaily stability 
and intradaily variability appear less disturbed if daytime activ-
ity levels are high.23 Increased sleep onset latency and subjective 
complaints on getting to bed at night and getting up in the morn-
ing are suggestive of a delayed phase in the circadian organization 
of sleep and wakefulness, which is in agreement with a recently 
reported delayed melatonin onset phase in children with ADHD-
related sleep-onset insomnia.35 Future studies with different pa-
rameters (e.g., temperature, melatonin) should shed further light 
on circadian patterning in participants with ADHD: do they go 
to bed later because they are too restless to sleep or because they 
show a phase delay in their circadian rhythm?
Our fourth research question was “What are the effects of 
treatment with Mph on activity, sleep parameters, and circadian 
rhythm in adults with ADHD?” No effects of Mph on daytime 
or nighttime activity level were found in our placebo-controlled 
study, thus disproving the suggested trend towards decreased 
nocturnal activity with stimulant treatment in adult ADHD in one 
previous open-label study.6 Our results agree with earlier studies 
on stimulant treatment in childhood ADHD, reporting no effect on 
nocturnal activity.36 
As to the effect of Mph on sleep parameters, Mph induced a 
delay in bedtime and sleep start, and increased sleep onset latency. 
As a result, the sleep duration decreased. In agreement with our 
ﬁndings, child ADHD studies have reported longer sleep onset la-
tency and shorter total sleep time as measured by actigraphy after 
stimulant treatment.19,36 An interesting result in our study was im-
provement of sleep quality, as reﬂected by fewer nocturnal awak-
enings, and an increase in the average duration of within-night 
periods of uninterrupted sleep. In agreement with the objective 
sleep quality improvement, participants indicated that they woke 
up fewer times during the night with medication, as was also 
found in a previous study on the effects of stimulants on sleep in 
adult ADHD.6 Our results are in part similar and in part contra-
dictory to the results of Schwartz et al.,19 where both quality and 
quantity of sleep deteriorated with medication. A possible expla-
nation for our results can be found in the timing of the last dose 
of medication, which was at 20:00. This makes the possibility of 
rebound (and thus worse sleep) less likely. In children, stimulants 
are often given during the day to facilitate behavior during school 
hours, and not in the evening. This might increase the chance of 
rebound early in the evening, and lead to bedtime resistance and 
sleep problems. Kent et al. reported that children with ADHD de-
rived substantial symptom reduction from Mph administered late 
in the afternoon, with no untoward effects on sleep.37
Regarding the effect of Mph on the circadian organization of 
the rest-activity rhythm, it delayed the onset of the least active 
period. This result was in accordance with the effects of medica-
tion on the sleep parameters, which were a delay in bedtime and 
sleep start, and longer sleep onset latency. A somewhat surprising 
result was an increased fragmentation of periods of rest and ac-
tivity (IV). The value was still below that of NCs in the baseline 
comparison, so the increase might be seen as an effect towards 
normalization of fragmentation. The most likely explanation of 
the high baseline fragmentation level (IV) is that daytime activ-
ity levels may be continuously at a high level in ADHD, but in-
terspersed with brief periods of a lower activity level in healthy 
controls, thus resulting in a higher variability in controls. This in-
terpretation would then suggest that the Mph-induced increase in 
fragmentation could result from an increased number of brief pe-
riods of decreased activity, rather than by a continuously lowering 
of activity level. This is in line with the fact that the net decrease 
in daytime activity (M10) was slight and non-signiﬁcant.
Age, sex, and seasonal effects were included in the analyses 
because of the previously established inﬂuence of these variables 
on sleep-wake parameters. Within the ADHD group, it was strik-
ing that females showed a higher mean activity count during the 
day than males. This is rather surprising, since in children with 
ADHD, it has been thought that girls more often show the inat-
tentive subtype, with less profound motor hyperactivity, whereas 
boys are supposedly more often affected by the hyperactive/im-
pulsive subtype of the disorder.38 There is tentative evidence both 
for lack of differences at the symptom level between sexes in 
adult ADHD,39 and for overrepresentation of the hyperactive/im-
pulsive subtype among adult women with the disorder,14 so the 
difference in activity level warrants further investigation. In our 
ADHD group, there were more women (65%) than men (38%) 
with a light, medium, or high physical component in their occu-
pation, which may partly explain this difference (the correlation 
between physical component of occupation and M10 was 0.24). 
Differences in comorbid disorders between sexes may inﬂuence 
the activity level as well. 
The most outstanding result with respect to age was that sleep 
seems to become more consolidated (as indicated by increased 
sleep efﬁciency, fewer wake bouts, and longer sleep bouts) in the 
ADHD group with age. These are remarkable ﬁndings given the 
literature on increasing sleep problems with age in the healthy 
population.40 The ﬁndings may be related to a decline in hyperac-
tive symptoms with age.21
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Our study has some limitations that should be taken into ac-
count in future investigations of activity and sleep in adult ADHD. 
The presence of primary and secondary sleep disorders in adult 
ADHD is possible; a thorough investigation of such disturbances 
in adult ADHD has not yet been undertaken. 
Our present work should be seen a ﬁrst step in elucidating 
sleep-wake rhythms in adult ADHD and the effect of Mph. With 
respect to the latter, it should be mentioned that our compliance 
rate seemed rather low (20 out of 28 as measured with the Memos 
device). Although our deﬁnition of compliance may have led to 
labeling people as noncompliant when in fact they did take their 
medication (outside the 15-min limit), this result warrants careful 
monitoring of compliance in future medication trials. Counting of 
leftover pills suggested a higher compliance rate in our trial, but 
this is a less trustworthy measure of compliance, since partici-
pants can easily alter the number of leftover pills. The demonstra-
tion of increased sleep onset latency, decreased sleep efﬁciency, 
and shorter periods of uninterrupted sleep in adult ADHD subjects 
warrants more extensive and expensive research including poly-
somnography, circadian analyses of parameters like body tem-
perature and melatonin, and a complete screening by a sleep clini-
cian. Furthermore, even though we found no relation to symptoms 
of depression or anxiety, it would be important to examine the ef-
fect of other possible comorbid disorders. Other important issues 
for further research are: the long-term effects of stimulant treat-
ment on sleep parameters, daytime sleepiness, effects of sleep 
disturbances on problems in cognitive functioning that have been 
related to ADHD, issues with respect to clinical responders versus 
non-responders, and ADHD subtypes.
In conclusion, we have established that adult ADHD is associ-
ated with elevated and less variable daytime activity, worse objec-
tive and subjective sleep quality, and a more rigid daily schedule 
of activity. Treatment with Mph improved sleep quality in spite 
of prolonging sleep onset latency and decreasing total sleep time. 
At present, one can only speculate on the potential mechanisms 
of the disturbed sleep in adult ADHD, and beneﬁcial effects of 
Mph. In rather general terms, the presumed derailment of arousal 
regulation in adult ADHD appears not to be limited to the day-
time. The reduction of consolidated periods of sleep within the 
night and the decreased sleep efﬁciency indicate a deﬁcit in the 
ability to consolidate the sleep state. In agreement with the pre-
sumed normalizing action of Mph on daytime arousal regula-
tion, it also appeared to normalize the nocturnal deﬁcit, i.e., it 
promoted consolidated sleep by reducing the number of awaken-
ings and increasing the average duration of within-night periods 
of uninterrupted sleep. Studies utilizing temperature or melatonin 
assessment under more controlled circumstances are needed to 
further evaluate the possibility of a circadian phase delay. Our 
data suggest that sleep problems are inherent in adult ADHD, both 
objectively and subjectively, and deserve further investigation in-
cluding controlled circadian studies, polysomnography and a clin-
ical sleep investigation. Our data also suggest that sleep problems 
are neither caused by nor worsened with stimulant treatment in 
this population. On the contrary, stimulants improve the quality 
of sleep in adults with ADHD.
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